SCHIZOPHRENIA AND NICOTINIC RECEPTORS

被引:189
作者
FREEDMAN, R
ADLER, LE
BICKFORD, P
BYERLEY, W
COON, H
CULLUM, CM
GRIFFITH, JM
HARRIS, JG
LEONARD, S
MILLER, C
MYLESWORSLEY, M
NAGAMOTO, HT
ROSE, G
WALDO, M
机构
[1] UNIV COLORADO, SCH MED, DEPT PSYCHIAT, DENVER, CO 80262 USA
[2] UNIV COLORADO, SCH MED, DEPT PHARMACOL, DENVER, CO 80262 USA
[3] VET ADM MED CTR, DENVER, CO 80220 USA
[4] UNIV UTAH, SCH MED, DEPT PSYCHIAT, SALT LAKE CITY, UT 84112 USA
[5] UNIV TEXAS, SW MED SCH, DEPT PSYCHIAT, DALLAS, TX 75230 USA
[6] VET ADM MED CTR, DALLAS, TX 75216 USA
关键词
D O I
10.3109/10673229409017136
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Patients with schizophrenia often cannot respond to important features of their environment and filter out irrelevant stimuli. This dysfunction could be related to an underlying defect in inhibition - i.e., the brain's ability to alter its sensitivity to repeated stimuli. One of the neuronal mechanisms responsible for such inhibitory gating involves the activation of cholinergic nicotinic receptors in the hippocampus. These receptors are diminished in many specimens of hippocampal brain tissue obtained postmortem from schizophrenic patients. In living schizophrenic patients, stimulation of cholinergic receptors by nicotine transiently restores inhibitory gating of evoked responses to sensory stimuli. Many people with schizophrenia are heavy smokers, but the properties of the nicotinic receptor favor only short-term activation, which may explain why cigarette smoking is only a transient symptomatic remedy. This paper reviews the clinical phenomenology of inhibitory gating deficits in people with schizophrenia, the neurobiology of such gating mechanisms, and the evidence that some individuals with the disorder may have a heritable deficit in the nicotinic cholinergic receptors involved in this neurobiological function. Inhibitory gating deficits are only partly normalized by neuroleptic drugs and are thus a target for new therapeutic strategies for schizophrenia.
引用
收藏
页码:179 / 192
页数:14
相关论文
共 50 条
  • [41] BINDING OF SEMIRIGID NICOTINIC AGONISTS TO NICOTINIC AND MUSCARINIC RECEPTORS
    SPIVAK, CE
    WATERS, JA
    ARONSTAM, RS
    MOLECULAR PHARMACOLOGY, 1989, 36 (01) : 177 - 184
  • [42] Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker
    Hashimoto, Kenji
    CURRENT PHARMACEUTICAL DESIGN, 2015, 21 (26) : 3797 - 3806
  • [43] α7 nicotinic acetylcholine receptors as therapeutic targets in schizophrenia: Update on animal and clinical studies and strategies for the future
    Terry, Alvin V., Jr.
    Callahan, Patrick M.
    NEUROPHARMACOLOGY, 2020, 170
  • [44] Involvement of nicotinic acetylcholine receptors in behavioral abnormalities and psychological dependence in schizophrenia-like model mice
    Noda, Yukihiro
    Uchida, Mizuki
    Mouri, Akihiro
    Yamada, Shokuro
    Goto, Sakika
    Kitagaki, Shinji
    Mamiya, Takayoshi
    Kushima, Itaru
    Arioka, Yuko
    Ozaki, Norio
    Yoshimi, Akira
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2020, 41 : 92 - 105
  • [45] Alpha7 Neuronal Nicotinic Receptors as Targets for Novel Therapies to Treat Multiple Domains of Schizophrenia
    Kucinski, Aaron J.
    Stachowiak, Michal K.
    Wersinger, Scott R.
    Lippiello, Patrick M.
    Bencherif, Merouane
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2011, 12 (03) : 437 - 448
  • [46] ''Neuronal'' nicotinic acetylcholine receptors
    Lukas, RJ
    JOURNAL OF NEUROCHEMISTRY, 1997, 69 : S161 - S161
  • [47] Targeting Nicotinic Receptors For Asthma
    Pabelick, C.
    Thompson, M.
    Sine, S.
    Prakash, Y. S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [48] Nicotinic acetylcholine receptors and cancer
    Dang, Ningning
    Meng, Xianguang
    Song, Haiyan
    BIOMEDICAL REPORTS, 2016, 4 (05) : 515 - 518
  • [49] DISULFIDE BONDS IN NICOTINIC RECEPTORS
    MITTAG, TW
    TORMAY, A
    FEDERATION PROCEEDINGS, 1970, 29 (02) : A547 - +
  • [50] Nicotinic acetylcholine receptors and imaging
    Gündisch, D
    CURRENT PHARMACEUTICAL DESIGN, 2000, 6 (11) : 1143 - 1157